E. M. Bevers, M. Galli, T. Barbui, et al., “Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin,” Thromb Haemost, Vol. 66, 1991, pp. 629-632.
 S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey and R. Cervera, “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” J Thromb Haemost, Vol.4, 2006, pp. 295-306.
 H. P. McNeil, R. J. Simpson, C. N. Chesterman and S.A. Krilis, “Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2- glycoprotein 1 (apolipoprotein H),” Proc Natl Acad Sci USA, Vol. 87, 1990, pp. 4120-4125.
 G. S. Cooper, M.A. Dooley, E. L. Treadwell, E.W. St Clair, C. G. Parks and G.S. Gilkeson, “Hormonal, environmental, and infectious risk factors for developing Systemic Lupus Erythematosus,” Arthritis Rheum, Vol. 41, No. 10, 1998, pp.171417-24.
 V. D. D’Agati and G.B Appel, “Lupus Nephritis: Pathology and Pathogenesis,” D.J .Wallace, B.H. Hahn, eds. Dubois’ Lupus Erythematosus.7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 1094-111.
 H. Zheng, Y. Chen, W. Ao, Y. Shen, X. W. Chen, M. Dai, X. D. Wang, Y. C. Yan and C. D. Yang, “Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases,” Arthritis Res Ther, Vol.11, No. 3, 2009, R93. Epub 2009 Jun 22.
 M.L. Davies, S.P. Young, K.Welsh, M.Bunce, B.P. Wordsworth, et al., “Immune responses to native β2-glycoprotein I in patients with Systemic Lupus Erythematosus and the anti-phospholipid syndrome,” Rheumatology, Vol 41, 2002, pp. 395-400.
 M. Jallouli, M. Frigui, M. B. Hmida, S. Marzouk, N. Kaddour and Z. Bahloul, “Clinical and immunological manifestations of Systemic Lupus Erythematosus: study on 146 south Tunisian patients,” Saudi J Kidney Dis Transpl, Vol. 19, No. 6, 2008, pp.1001-1008.
 E. Descloux, I. Durieu, P. Cochat, D. Vital Durand, J Ninet, N. Fabien and R. Cimaz, “Pediatric Systemic Lupus Erythematosus: prognostic impact of antiphospholipid antibodies,” Rheumatology (Oxford), Vol. 47, No. 2, 2008, pp.183-187.
 C. Bombardier, F. F. Gladmsn, M. B. Urowit, D. Caron and C. H. Chang, “Derivation of SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arch Rheum, Vol. 35, 1995, pp. 630-640.
 J. J. Weening, V. D. Agati, M. M. Schwartz, S. V. Seshan, C. E. Alpers and G. B. Appel, “The classification of glomerulonephritis in Systemic Lupus Erythematosus Re visited,” J Am Soc Nephrol, Vol.15, No. 2, 2004, pp. 241-250.
 L. O. Carreras, J. Vermylen, B. Spitz and A. Van Assche, “Lupus anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death,” Br J Obstet Gynaecol, Vol. 88, No. 9, 1981, pp.890-894.
 M. L. Boey, C.B. Colaco, A. E. Gharavi, K. B. Elkon, S. Loizou and G. R. Hughes, “Thrombosis in Systemic Lupus Erythematosus: striking association with the presence of circulating lupus Anticoagulant,” Br Med J (Clin Res Ed, Vol. 8; No. 287(6398), 1983, pp. 1021-1023.
 E. N. Harris, A. E. Gharavi and M. L. Boey, “Anti cardiolipin antibody detection by radioimmunoassay and association with thrombosis in Systemic Lupus Erythematosus,” Lancet, Vol. 2, 1983, pp. 1211-1214.
 G. A. Mostafa, D.H. Ibrahim, A. A. Shehab and A.K. Mohammed, “The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric Systemic Lupus Erythematosus,” J Neuroimmunol, Vol. 8, No. 227(1-2), 2010, pp.195-201.
 T. Gould, M. Tikly, R. Asherson, S. Loizou and S. Singh, “Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with Systemic Lupus Erythematosus,” Scand J Rheumatol, Vol. 35, No. 1, 2006, pp.29-34.
 K. S. Woo, K.E. Kim, J.M. Kim, J. Y. Han, W. T. Chung and K. H. Kim, “Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti- beta2-glycoprotein I antibodies in patients with SLE,” Korean J Lab Med, Vol 30, No. 1, 2010, pp.38-44.
 A. Shrivastava, S. Dwivedi, A. Aggarwal and R. Misra, “Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with Systemic Lupus Erythematosus: association with the presence of seizures,” Lupus, Vol. 10, No. 1, 2001, pp. 45-50.
 Z. S. Sarabi, E. Chang, R. Bobba, D. Ibanez, D. Gladman, M. Urowitz et al., “Incidence rates of arterial and venous thrombosis after diagnosis and Systemic Lupus Erythematosus,” Arthritis & Rheumatism, Vol. 53, No. 4, 2005, pp.609-612.
 M. Petri, M. Golbus, R. Anderson, Q. Whiting-O’Keefe, L. Corash and D. Hellmann, “Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled prospective study of forty-four women,” Arthritis Rheum, Vol 30, 1987, pp.601-606.